NanoBio announces positive data for next-generation flu vaccine

NanoBio, a spin-off from the University of Michigan, recently passed a major milestone when it announced initial positive data from an early-stage human clinical trial of its next-generation influenza vaccine.

The nanoparticle flu vaccine, known as NB-1008, is unique because it is capable of eliciting an immune response in the bloodstream and also in the mucosal membranes, like those that line nasal passages, according to It is in the nasal passages where people most commonly acquire pathogens.

This kind of double immunity has never been demonstrated before in flu vaccines that are injected into muscle tissue, or those, like MedImmune’s FluMist, that are available in nasal sprays, according to

“We did extensive testing, mice, ferrets, rabbits, so this study was a really a proof of concept for us in man,” David Peralta, NanoBio’s chief operating officer, told

NanoBio took an existing flu vaccine that was commercially available and merged it with a nanoparticle that was designed to interact with the antigen-presenting cells in the mucosal lining of the nose. The antigen-presenting cells trigger an immune response among other cells in the area.

Passing the first human test for efficacy and safety is major step, but it usually takes testing on thousands of patients in clinical trials before a new vaccine is accepted. Beyond generating an immune response, a vaccine candidate must prove that people are actually better protected after being exposed to the flu.

NanoBio might need the help of a larger biopharmaceutical partner to accomplish this, and is already scouting for options. The company has already stoked interest with potential partners that are curious about applying the NanoBio technology to other vaccines.